The biotech firm Biogen (BIIB) has been making strategic moves to strengthen and expand its growth portfolio. The company has announced the acquisition of Apellis, a move designed to boost its growth outlook and accelerate its expansion into nephrology. This action will also enhance Biogen's portfolio in immunology and rare disease areas. In addition, Element Squared LLC has bought 15,051 shares in Biogen. The company also received approval for its SPINRAZA regimen and delivered positive data on lupus. The recent developments have resulted in several price target boosts for Biogen. Despite mixed recent share returns, some believe the company is undervalued, driven by its promising pipeline. The company's stock sank amid soaring market tendencies, but its price targets have been consistently raised by financial institutions such as Canaccord Genuity, H.C. Wainwright, and Oppenheimer. Furthermore, Biogen is strengthening its immunology portfolio by acquiring Apellis for $5.6B, despite some volatility in its share price. New data for SMA and the introduction of Phase 3 plans have also highlighted the company's growth focus.
Biogen BIIB News Analytics from Mon, 21 Jul 2025 07:00:00 GMT to Sat, 04 Apr 2026 08:36:54 GMT - Rating 8 - Innovation 6 - Information 8 - Rumor 1
